Hydrogen Gas in Cancer Treatment

Sai Li†1, Rongrong Liao†2, Xiaoyan Sheng†2, Xiaojun Luo3, Xin Zhang1, Xiaomin Wen3, Jin Zhou2* and Kang Peng1,3*

†Department of Pharmacy, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China, 2Nursing Department, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China, 3The Centre of Preventive Treatment of Disease, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China

Gas signaling molecules (GSMs), composed of oxygen, carbon monoxide, nitric oxide, hydrogen sulfide, etc., play critical roles in regulating signal transduction and cellular homeostasis. Interestingly, through various administrations, these molecules also exhibit potential in cancer treatment. Recently, hydrogen gas (formula: H2) emerges as another GSM which possesses multiple bioactivities, including anti-inflammation, anti-reactive oxygen species, and anti-cancer. Growing evidence has shown that hydrogen gas can either alleviate the side effects caused by conventional chemotherapeutics, or suppress the growth of cancer cells and xenograft tumor, suggesting its broad potent application in clinical therapy. In the current review, we summarize these studies and discuss the underlying mechanisms. The application of hydrogen gas in cancer treatment is still in its nascent stage, further mechanistic study and the development of portable instruments are warranted.

Keywords: hydrogen gas, ROS, inflammation, combination, anti-cancer

INTRODUCTION

Gaseous signaling molecules (GSMs) refer to a group of gaseous molecules, such as oxygen (1), nitric oxide (2), carbon monoxide (3), hydrogen sulfide (4), sulfur dioxide (5, 6), ethylene (7, 8), etc. These gaseous molecules possess multiple critical functions in regulating cell biology in vivo via signal transduction (9). More importantly, certain GSMs could serve as therapeutic agents in primary cancer, as well as in multidrug-resistant cancer treatment when used by directly or certain pharmaceutical formulations (9–13). In addition, some of these GSMs can be generated in body via different bacteria or enzymes, such as nitric oxide, hydrogen sulfide, indicating that they are more compatible molecules that may exhibit less adverse effects compared with conventional chemotherapeutics (9, 14, 15). Recently, hydrogen gas has been recognized as another important GSM in biology, exhibiting appealing potential in health care for its role in preventing cell injury from various attacking (16–19).

With the formula of H2, hydrogen gas is the lightest molecule in the nature which only accounts for about 0.5 parts per million (ppm) of all the gas. Naturally, hydrogen gas is a colorless, odorless, tasteless, non-toxic, highly combustible gas which may form explosive mixtures with air in concentrations from 4 to 74% that can be triggered by spark, heat, or sunlight. Hydrogen gas can be generated in small amount by hydrogenase of certain members of the human gastrointestinal tract microbiota from unabsorbed carbohydrates in the intestine through degradation and metabolism (20, 21), which then is partially diffused into blood flow and released and detected in exhaled breath (20), indicating its potential to serve as a biomarker.
As the lightest molecule in nature, hydrogen gas exhibits appealing penetration property, as it can rapidly diffuse through cell membranes (22, 23). Study in animal model showed that, after orally administration of hydrogen super-rich water (HSRW) and intra-peritoneal administration of hydrogen super-rich saline (HSRS), the hydrogen concentration reached the peak at 5 min; while it took 1 min by intravenous administration of HSRS (23). Another in vivo study tested the distribution of hydrogen in brain, liver, kidney, mesentery fat, and thigh muscle in rat upon inhalation of 3% hydrogen gas (24). The concentration order of hydrogen gas, when reached saturated status, was liver, brain, mesentery, muscle, kidney, indicating various distributions among organs in rats. Except the thigh muscle required a longer time to saturate, the other organs need 5–10 min to reach Cmax (maximum hydrogen concentration). Meanwhile, the liver had the highest Cmax (24). The information may direct the future clinical application of hydrogen gas.

Although hydrogen gas was studied as a therapy in a skin squamous carcinoma mouse model back in 1975 (25), its potential in medical application has not been vastly explored until 2007, when Oshawa et al. reported that hydrogen could ameliorate cerebral ischemia-reperfusion injury by selectively reducing cytotoxic reactive oxygen species (ROS), including hydroxyl radical (•OH) and peroxynitrite (ONOO⁻) (26), which then provoked a worldwide attention. Upon various administrative formulations, hydrogen gas has been served as a therapeutic agent for a variety of illnesses, such as Parkinson’s disease (27, 28), rheumatoid arthritis (29), brain injury (30), ischemic reperfusion injury (31, 32), and diabetes (33, 34), etc.

More importantly, hydrogen gas has been shown to improve clinical end-points and surrogate markers, from metabolic diseases to chronic systemic inflammatory disorders to cancer (17). A clinical study in 2016 showed that inhalation of hydrogen gas was safe in patients with post-cardiac arrest syndrome (35), its further therapeutic application in other diseases became even more appealing.

In the current review, we take a spot on its application in cancer treatment. Typically, hydrogen gas may exert its biofunctions via regulating ROS, inflammation and apoptosis events.

**HYDROGEN GAS SELECTIVELY SCAVENGES HYDROXYL RADICAL AND PEROXYNITRITE, AND REGULATES CERTAIN ANTIOXIDANT ENZYMES**

By far, many studies have indicated that hydrogen gas doesn’t target specific proteins, but regulate several key players in cancer, including ROS, and certain antioxidant enzymes (36).

ROS refers to a series of unstable molecules that contain oxygen, including singlet oxygen (O₂•), hydrogen peroxide (H₂O₂), hydroxyl radical (•OH), superoxide (•O₂⁻), nitric oxide (NO•), and peroxynitrite (ONOO⁻), etc. (37, 38). Once generated in vivo, due to their high reactivity, ROS may attack proteins, DNA/RNA and lipids in cells, eliciting distinct damage that may lead to apoptosis. The presence of ROS can produce cellular stress and damage that may produce cell death, via a mechanism known as oxidative stress (39, 40). Normally, under physical condition, cells including cancer cells maintain a balance between generation and elimination of ROS, which is of paramount importance for their survival (41, 42). The over-produced ROS, resulted from imbalance regulatory system or outer chemical attack (including chemotherapy/radiotherapy), may initiate inner apoptosis cascade, causing severely toxic effects (43–45).

Hydrogen gas may act as a ROS modulator. First, as shown in Ohsawa et al.’s study, hydrogen gas could selectively scavenge the most cytotoxic ROS, •OH, as tested in an acute rat model of cerebral ischemia and reperfusion (26). Another study also confirmed that hydrogen gas might reduce the oxygen toxicity resulted from hyperbaric oxygen via effectively reducing •OH (46).

Second, hydrogen may induce the expression of some antioxidant enzymes that can eliminate ROS, and it plays key roles in regulating redox homeostasis of cancer cells (42, 47). Studies have indicated that upon hydrogen gas administration, the expression of superoxide dismutase (SOD) (48), heme oxygenase-1 (HO-1) (49), as well as nuclear factor erythroid 2-related factor 2 (Nrf2) (50), increased significantly, strengthening its potential in eliminating ROS.

By regulating ROS, hydrogen gas may act as an adjuvant regimen to reduce the adverse effects in cancer treatment while at the same time doesn’t abrogate the cytotoxicity of other therapy, such as radiotherapy and chemotherapy (48, 51). Interestingly, due the over-produced ROS in cancer cells (38), the administration of hydrogen gas may lower the ROS level at the beginning, but it provokes much more ROS production as a result of compensation effect, leading to the killing of cancer cells (52).

**HYDROGEN GAS SUPPRESSES INFLAMMATORY CYTOKINES**

Inflammatory cytokines are a series of signal molecules that mediate the innate immune response, whose dys-regulation may contribute in many diseases, including cancer (53–55). Typical inflammatory cytokines include interleukins (ILs) excreted by white blood cells, tumor necrosis factors (TNFs) excreted by macrophages, both of which have shown close linkage to cancer initiation and progression (56–59), and both of ILs and TNFs can be suppressed by hydrogen gas (60, 61).

Inflammation induced by chemotherapy in cancer patients not only causes severely adverse effects (62, 63), but also leads to cancer metastasis, and treatment failure (64, 65). By regulating inflammation, hydrogen gas can prevent tumor formation, progression, as well as reduce the side effects caused by chemotherapy/radiotherapy (66).

**HYDROGEN GAS INHIBITS/INDUCES APOPTOSIS**

Apoptosis, also termed as programed cell death, can be triggered by extrinsic or intrinsic signals and executed by different molecular pathways, which serve as one efficient strategy for
cancer treatment (67, 68). Generally, apoptosis can be induced by (1) provoking the death receptors of cell surface (such as Fas, TNF receptors, or TNF-related apoptosis-inducing ligand), (2) suppressing the survival signaling (such as epidermal growth factor receptor, mitogen-activated protein kinase, or phosphoinositide 3-kinases), and (3) activating the pro-apoptotic B-cell lymphoma-2 (Bcl-2) family proteins, or down-regulating anti-apoptosis proteins (such as X-linked inhibitor of apoptosis protein, surviving, and the inhibitor of apoptosis) (69, 70).

Hydrogen gas can regulate intracellular apoptosis by impacting the expression of apoptosis-related enzymes. At certain concentration, it can either serve as apoptosis-inhibiting agent via inhibiting the pro-apoptotic B-cell lymphoma-2-associated X protein (Bax), caspase-3, 8, 12, and enhancing the anti-apoptotic B-cell lymphoma-2 (Bcl-2) (71), or as apoptosis-inducing agent via the contrast mechanisms (72), suggesting its potential in protecting normal cells from anti-cancer drugs or in suppressing cancer cells.

**HYDROGEN GAS EXHIBITS POTENTIAL IN CANCER TREATMENT**

**Hydrogen Gas Relieves the Adverse Effects Related to Chemotherapy/Radiotherapy**

Chemotherapy and radiotherapy remain the leading strategies to treat cancer (73, 74). However, cancer patients receiving these treatments often experience fatigue and impaired quality of life (75–77). The skyrocketed generation of ROS during the treatment is believed to contribute in the adverse effects, resulting in remarkable oxidative stress, and inflammation (41, 42, 78). Therefore, benefited from its anti-oxidant and anti-inflammatory and other cell protective properties, hydrogen gas can be adopted as an adjuvant therapeutic regimen to suppress these adverse effects.

Under treatment of epidermal growth factor receptor inhibitor gefitinib, patients with non-small cell lung cancer often suffer with severe acute interstitial pneumonia (79). In a mice model treated with oral administration of gefitinib and intraperitoneal injection of naphthalene which induced severely lung injury due to oxidative stress, hydrogen-rich water treatment significantly reduced the inflammatory cytokines, such as IL-6 and TNFα in the bronchoalveolar lavage fluid, leading to a relieve of lung inflammation. More importantly, hydrogen-rich water didn’t impair the overall anti-tumor effects of gefitinib both in vitro and in vivo, while in contrast, it antagonized the weight loss induced by gefitinib and naphthalene, and enhanced the overall survival rate, suggesting hydrogen gas to be a promising adjuvant agent that has potential to be applied in clinical practice to improve quality of life of cancer patients (80).

Doxorubicin, an anthracycline antibiotic, is an effective anticancer agent in the treatment of various cancers, but its application is limited for the fatal dilated cardiomyopathy and hepatotoxicity (81, 82). One in vivo study showed that intraperitoneal injection of hydrogen-rich saline ameliorated the mortality, and cardiac dysfunction caused by doxorubicin. This treatment also attenuated histopathological changes in serum of rats, such as the serum brain natriuretic peptide (BNP), aspartate transaminase (AST), alanine transaminase (ALT), albumin and malondialdehyde (MDA) levels. Mechanistically, hydrogen-rich saline significantly lowered the ROS level, as well as inflammatory cytokines TNF-α, IL-1β, and IL-6 in cardiac and hepatic tissue. Hydrogen-rich saline also induced less expression of apoptotic Bax, cleaved caspase-3, and higher anti-apoptotic Bcl-2, resulting in less apoptosis in both tissues (71). This study suggested that hydrogen-rich saline treatment exerted its protective effects via inhibiting the inflammatory TNF-α/IL-6 pathway, increasing the cleaved C8 expression and Bcl-2/Bax ratio, and attenuating cell apoptosis in both heart and liver tissue (71).

Hydrogen-rich water also showed renal protective effect against cisplatin-induced nephrotoxicity in rats. In the studies, blood oxygenation level-dependent (BOLD) contrast magnetic resonance images (MRI) acquired in different treated group showed that the creatinine and blood urea nitrogen (BUN) levels, two parameters that related to nephrotoxicity, were significantly higher in cisplatin treated group than those in the control group. Hydrogen-rich water treatment could significantly reverse the toxic effects, and it showed much higher transverse relaxation rate by eliminating oxygen radicals (83, 84).

Another study showed that both inhaling hydrogen gas (1% hydrogen in air) and drinking hydrogen-rich water (0.8 mM hydrogen in water) could reverse the mortality, and body-weight loss caused by cisplatin via its anti-oxidant property. Both treatments improved the metamorphosis, accompanied with decreased apoptosis in the kidney, and nephrotoxicity as assessed by serum creatinine and BUN levels. More importantly, hydrogen didn’t impair the anti-tumor activity of cisplatin against cancer cell lines in vitro and in tumor-bearing mice (85). Similar results were also observed in Meng et al.’s study, as they showed that hydrogen-rich saline could attenuate the follicle-stimulating hormone release, elevate the level of estrogen, improve the development of follicles, and reduce the damage to the ovarian cortex induced by cisplatin. In the study, cisplatin treatment induced higher level of oxidation products, suppressed the antioxidant enzyme activity. The hydrogen-rich saline administration could reverse these toxic effects by reducing MDA and restoring the activity of superoxide dismutase (SOD), catalase (CAT), two important anti-oxidant enzymes. Furthermore, hydrogen-rich saline stimulated the Nrf2 pathway in rats with ovarian damage (86).

The mFOLFOX6 regimen, composed with folinic acid, 5-fluorouracil, and oxaliplatin, is used as first-line treatment for metastatic colorectal cancer, but it also confers toxic effects to liver, leading to bad quality of life of patient (87, 88). A clinical study was conducted in China by investigating the protective effect of hydrogen-rich water on hepatic function of colorectal cancer patients (144 patients were enrolled and 136 of them were include in the final analysis) treated with mFOLFOX6 chemotherapy. The results showed that the placebo group exhibited damaging effects caused by mFOLFOX6 chemotherapy as measured by the elevated levels of ALT, AST and indirect bilirubin (IBIL), while the hydrogen-rich water combinational treatment group exhibited no differences in liver function during the treatment, probably due to its antioxidant activity, indicating
It is a promising protective agent to alleviate the mFOLFOX6-related liver injury (51).

Most of the ionizing radiation-induced adverse effects to normal cells are induced by hydroxyl radicals. The combination of radiotherapy with certain forms of hydrogen gas may be beneficial to alleviate these side effects (89). Indeed, several studies found that hydrogen could protect cells and mice from radiation (48, 90).

As tested in a rat model of skin damage established by using a 44 Gy electronic beam, the treated group by hydrogen-rich water exhibited higher lever of SOD activity and lower MDA and IL-6 in the wounded tissues than the control group and the distilled water group. Furthermore, hydrogen-rich water shortened the healing time and increased the healing rate of skin injury (48).

Gastrointestinal toxicity is a common side effect induced by radiotherapy, which impairs the life quality of cancer patients (91). As shown in Xiao et al.’s study in mice model, hydrogen-water administration via oral gavage increased the survival rate and body weight of mice which were exposed to total abdominal irradiation, accompanied with an improvement in gastrointestinal tract function and the epithelial integrity of the small intestine. Further microarray analysis revealed that hydrogen-water treatment up-regulated miR-1968-5p, which then up-regulated its target myeloid differentiation primary response gene 88 (Mdy88, a mediator in immunopathology, and gut microbiota dynamics of certain intestinal diseases involving toll-like receptors 9) expression in the small intestine after total abdominal irradiation (92).

Another study conducted in clinical patients with malignant liver tumors showed that the consumption of hydrogen-rich water for 6 weeks reduced the level of reactive oxygen metabolite, hydroperoxide, and maintained the biologic antioxidant activity in the blood. Importantly, scores of quality of life during radiotherapy were significantly improved in hydrogen-rich water group compared to the placebo water group. Both groups exhibited similar tumor response to radiotherapy, indicating that the consumption of hydrogen-rich water reduced the radiation-induced oxidative stress while at the same time didn’t compromise anti-tumor effect of radiotherapy (93).

**Hydrogen Gas Acts Synergistically With Thermal Therapy**

Recently, one study found that hydrogen might enhance the effect of photothermal therapy. Zhao et al. designed the hydrogenated Pd nanocrystals (named as PdH$_{0.2}$) as multifunctional hydrogen carrier to allow the tumor-targeted delivery (due to 30 nm cubic Pd nanocrystal) and controlled release of bio-reductive hydrogen (due to the hydrogen incorporated into the lattice of Pd). As shown in this study, hydrogen release could be adjusted by the power and duration of near-infrared (NIR) irradiation. Treatment of PdH$_{0.2}$ nanocrystals plus NIR irradiation lead to higher initial ROS loss in cancer cells, and the subsequent ROS rebound was also much higher than that in normal cells, resulting in more apoptosis, and severely mitochondrial metabolism inhibition in cancer cells but not in normal cells. The combination of PdH$_{0.2}$ nanocrystals with NIR irradiation significantly enhanced the anticancer efficacies of thermal therapy, achieving a synergetic anticancer effect. *In vivo* safety evaluation showed that the injection dose of 10 mg kg$^{-1}$ PdH$_{0.2}$ nanocrystals caused no death, no changes of several blood indicators, and no affected functions of liver and kidney. In 4T1 murine breast cancer tumor model and B16-F10 melanoma tumor model, the combined PdH$_{0.2}$ nanocrystals and NIR irradiation therapy exhibited a synergetic anticancer effect, leading to remarkable tumor inhibition when compared with thermal therapy. Meanwhile, the combination group showed no visible damage to heart, liver, spleen, lung, and kidney, indicating suitable tissue safety and compatibility (52).

**Hydrogen Gas Suppresses Tumor Formation**

Li et al. reported that the consumption of hydrogen-rich water alleviated renal injury caused by Ferric nitrolotriacetate (Fe-NTA) in rats, evidenced by decreased levels of serum creatinine and BUN. Hydrogen-rich water suppressed the Fe-NTA-induced oxidative stress by lowering lipid peroxidation, ONOO$^-$, and inhibiting the activities of NADPH oxidase and xanthine oxidase, as well as by up-regulating antioxidant catalase, and restoring mitochondrial function in kidneys. Consequently, Fe-NTA-induced inflammatory cytokines, such as NF-$\kappa$B, IL-6, and monocyte chemoattractant protein-1 were significantly alleviated by hydrogen treatment. More importantly, hydrogen-rich water consumption inhibited several cancer-related proteins expression, including vascular endothelial growth factor (VEGF), signal transducer and activator of transcription 3 (STAT3) phosphorylation, and proliferating cell nuclear antigen (PCNA) in rats, resulting in lower incidence of renal cell carcinoma and the suppression of tumor growth. This work suggested that hydrogen-rich water was a promising regimen to attenuate Fe-NTA-induced renal injury and suppress early tumor events (66).

Non-alcoholic steatohepatitis (NASH) due to oxidative stress induced by various stimuli, is one of the reasons that cause hepatocarcinogenesis (94, 95). In a mouse model, hydrogen-rich water administration lowered the hepatic cholesterol, peroxisome proliferator-activated receptor-$\alpha$ (PPAR$\alpha$) expression, and increased the anti-oxidative effects in the liver when compared with control and pioglitazone treated group (96). Hydrogen-rich water exhibited strong inhibitory effects to inflammatory cytokines TNF-$\alpha$ and IL-6, oxidative stress and apoptosis biomarker. As shown in NASH-related hepatocarcinogenesis model, in the group of hydrogen-rich water treatment, tumor incidence was lower and the tumor volumes were smaller than control and pioglitazone treated group. The above findings indicated that hydrogen-rich water had potential in liver protection and liver cancer treatment (96).

**Hydrogen Gas Suppresses Tumor Growth**

Not only working as an adjuvant therapy, hydrogen gas can also suppress tumor and tumor cells growth.

As shown in Wang et al.’s study, on lung cancer cell lines A549 and H1975 cells, hydrogen gas inhibited the cell proliferation, migration, and invasion, and induced remarkable apoptosis as tested by CCK-8, wound healing, transwell assays...
### TABLE 1 | The Summary of various formulation, application, mechanisms of H₂ in cancer treatment.

| Formulation       | Application                                                                 | Mechanism                                                                                   | References |
|-------------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------|
| H₂-rich water     | Prevention of lung injury induced by gefitinib                               | Inflammatory cytokines and oxidative stress inhibition                                      | (80)       |
|                   | Prevention of nephrotoxicity induced by cisplatin                            | Oxygen radicals elimination                                                                  | (83, 84)  |
|                   | Reversal of mortality and body-weight loss caused by cisplatin               | ROS and apoptosis inhibition                                                                 | (69)       |
|                   | Amelioration of liver toxicity induced by mFOLFOX6 regimen                   | Oxidative stress inhibition                                                                  | (51)       |
|                   | Reversal of skin damage established by 44 Gy electronic beam                | Inflammatory cytokines and oxidative stress inhibition                                      | (48)       |
|                   | Amelioration of gastrointestinal toxicity induced by radiotherapy           | miR-1968-5p up-regulation                                                                    | (92)       |
|                   | Improving the quality of life                                               | Antioxidant activity                                                                         | (93)       |
|                   | Renal injury prevention and tumor growth suppression                         | Inflammatory cytokines and oxidative stress inhibition                                      | (68)       |
|                   | Tumor incidence and growth suppression                                       | Inflammatory cytokines and oxidative stress inhibition, apoptosis induction                 | (96)       |
|                   | Cancer stem cells inhibition                                                | CSCs properties and angiogenesis inhibition                                                  | (99)       |
| H₂-rich saline    | Amelioration of cardiac dysfunction induced by doxorubicin                   | Inflammatory cytokines, ROS and apoptosis inhibition                                        | (71)       |
|                   | Damage of ovarian cortex induced by cisplatin                               | Nrf2 pathway stimulation                                                                     | (86)       |
| H₂ inhalation     | Reversal of toxicity to kidney caused by cisplatin                           | ROS and apoptosis inhibition                                                                  | (69)       |
|                   | Tumor growth suppression                                                     | Cell cycle arrest and apoptosis induction                                                    | (68)       |
|                   | Glioblastoma growth inhibition and survival rate enhancement                | Inhibition of CSCs properties and induction of glioma stem-like cell (GSC) differentiation | (100)      |
| H₂ Pd nanocrystals| Synergistic effect with thermal therapy                                      | ROS provoking                                                                               | (52)       |
| H₂-silica         | Cancer cell viability inhibition                                             | H₂O₂ induction, cell cycle arrest, and apoptosis induction                                  | (72)       |
and flow cytometry. Hydrogen gas arrested the cell cycle at G2/M stage on both cell lines via inhibiting the expression of several cell cycle regulating proteins, including Cyclin D1, CDK4, and CDK6. Chromosomes 3 (SMC3), a complex required for chromosome cohesion during the cell cycle (97), was suppressed by hydrogen gas via ubiquitinating effects. Importantly, in vivo study showed that under hydrogen gas treatment, tumor growth was significantly inhibited, as well as the expression of Ki-67, VEGF and SMC3. These data suggested that hydrogen gas could serve as a new method for the treatment of lung cancer (98).

Due to its physicochemical characteristics, the use of hydrogen gas has been strictly limited in hospital and medical facilities and laboratories. Li et al. designed a solidified hydrogen-occluding-silica (H2-silica) that could stably release molecular hydrogen into cell culture medium. H2-silica could concentration-dependently inhibit the cell viability of human esophageal squamous cell carcinoma (KYSE-70) cells, while it need higher dose to suppress normal human esophageal epithelial cells (HEEpiCs), indicating its selective profile. This effect was further confirmed by apoptosis and cell migration assay in these two cell lines. Mechanistic study revealed that H2-silica exerted its anticancer via inducing H2O2 accumulation, cell cycle arrest, and apoptosis induction mediated by mitochondrial apoptotic pathways (72).

Recently, hydrogen gas was found to inhibit cancer stem cells (CSCs). Hydrogen gas reduced the colony formation and sphere formation of human ovarian cancer cell lines Hs38.T and PA-1 cells via inhibiting the proliferation marker Ki67, stem cell markers CD34, and angiogenesis. Hydrogen gas treatment significantly inhibited the proliferation, invasion, migration of both Hs38.T and PA-1 cells. More important, inhalation of hydrogen gas inhibited the tumor volume significantly as shown in the Hs38.T xenografted BALB/c nude mice model (99).

Another recent study also confirmed the effects of hydrogen gas in suppressing glioblastoma (GBM), the most common malignant brain tumor. In vitro study indicated that hydrogen gas inhibited several markers involved in stemness, resulting in the suppression of sphere formation, cell migration, invasion, and colony formation of glioma cells. By inhaling hydrogen gas (67%) 1 h, 2 times per day, the GBM growth was significantly inhibited, and the survival rate was improved in a rat orthotopic glioma model (100).

**DISCUSSION**

Hydrogen gas has been recognized as one medical gas that has potential in the treatment of cardiovascular disease, inflammatory disease, neurodegenerative disorders, and cancer (17, 60). As a hydroxyl radical and peroxynitrite scavenger, and due to its anti-inflammatory effects, hydrogen gas may work to prevent/relieve the adverse effects caused by chemotherapy and radiotherapy without compromise their anti-cancer potential (as summarized in Table 1 and Figure 1). Hydrogen gas may also work alone or synergistically with other therapy to suppress tumor growth via inducing apoptosis, inhibiting CSCs-related and cell cycle-related factors, etc. (summarized in Table 1).

More importantly, in most of the research, hydrogen gas has demonstrated safety profile and certain selectivity property to cancer cells over normal cells, which is quite pivotal to clinical trials. One clinical trials (NCT03818347) is now undergoing to study the hydrogen gas in cancer rehabilitation in China.

By far, several delivery methods have proved to be available and convenient, including inhalation, drinking hydrogen-dissolved water, injection with hydrogen-saturated saline and taking a hydrogen bath (101). Hydrogen-rich water is nontoxic, inexpensive, easily administered, and can readily diffuse into tissues and cells (102), cross the blood-brain barrier (103), suggesting its potential in the treatment of brain tumor. Further portable devices that are well-designed and safe enough will be needed.

However, regarding its medicinal properties, such as dosage and administration, or possible adverse reactions and use in specific populations, less information is available. Its mechanism, target, indications are also not clear, further study are warranted.

**AUTHOR CONTRIBUTIONS**

SL, XW, JZ, and KP: conceptualization. SL, RL, XS, XL, XZ, JZ, and KP: writing. SL, RL, and XS: revising.

**FUNDING**

This work was supported in part by grants from the Natural Science Foundation of Guangdong Province (2018A030313987) and Traditional Chinese Medicine Bureau of Guangdong Province (20164015 and 20183009) and Science and Technology Planning Project of Guangdong Province (2016ZC0059).

**ACKNOWLEDGMENTS**

We thank Miss Ryma Iftikhar, Dhiviya Samuel, Mahnoor Shamsi (St. John’s University), and Mr. Muaz Sadeia for editing and revising the manuscript.

**REFERENCES**

1. De Bels D, Corazza F, Geronpre P, Balestra C. The normobaric oxygen paradox: a novel way to administer oxygen as an adjuvant treatment for cancer? Med Hypotheses. (2011) 76:467–70. doi: 10.1016/j.mehy.2010.11.022
2. Oliveira C, Benfeito S, Fernandes C, Cagide F, Silva T, Borges F. NO and HNO donors, nitrones, and nitroxides: past, present, and future. Med Res Rev. (2018) 38:1159–87. doi: 10.1002/med.21461
3. Vitek L, Gbelcova H, Muchova L, Vanova K, Zelenka J, Konickova R, et al. Antiproliferative effects of carbon monoxide on pancreatic cancer. Dig Liver Dis. (2014) 46:369–75. doi: 10.1016/j.dld.2013.12.007
4. Flannigan KL, Wallace JL. Hydrogen sulfide-based anti-inflammatory and chemopreventive therapies: an experimental approach. Curr Pharm Des. (2015) 21:3012–22. doi: 10.2174/138161282166150514105413
5. Li Z, Huang Y, Du J, Liu AD, Tang C, Qi Y, et al. Endogenous sulfur dioxide inhibits vascular calcification in association with the TGF-beta/Smad signaling pathway. *Int J Mol Sci.* (2016) 17:2666. doi: 10.3390/ijms17032666

6. Jin H, Liu AD, Holmberg L, Zhao M, Chen S, Yang J, et al. The role of sulfur dioxide in the regulation of mitochondrial cardiomyocyte apoptosis in rats with ischemia-reperfusion-induced myocardial injury. *Int J Mol Sci.* (2013) 14:10465–82. doi: 10.3390/ijms140510465

7. Iriyotu P, Oklestkova J, Strnad M. Crosstalk between brassinosteroids and ethylene during plant growth and under abiotic stress conditions. *Int J Mol Sci.* (2018) 19:3283. doi: 10.3390/ijms19103283

8. Paardekooper LM, van den Bogaart G, Kox M, Dingjan I, Neerincx AH, van den Bogaart G, Kox M, Dingjan I, Neerincx AH, et al. Ethylene, an early marker of systemic inflammation in humans. *Sci Rep.* (2017) 7:6889. doi: 10.1038/s41598-017-05930-9

9. Cui Q, Yang Y, Jia N, Wang QJ, Ren L, Yang DH, et al. Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. *Future Med. Chem.* (2019) 11:323–6. doi: 10.4155/fmc-2018-0403

10. Huang Z, Fu J, Zhang Y. Nitric oxide donor-based cancer therapy: advances and prospects. *J Med Chem.* (2017) 60:7671–35. doi: 10.1021/acs.jmedchem.7b00671

11. Ma Y, Yan Z, Deng X, Guo J, Hu J, Yu Y, et al. Anticancer effect of exogenous hydrogen sulfide in cisplatin-resistant A549/DDP cells. *Oncof Res.* (2018) 39:2699–77. doi: 10.3892/or.2018.6362

12. Zheng DW, Li B, Li CX, Xu L, Fan JX, Lei L, et al. Photocatalyzing CO2 to CO for enhanced cancer therapy. *Adv Mater.* (2017) 29:1703822. doi: 10.1002/adma.201703822

13. Chen J, Luo H, Liu Y, Zhang W, Li H, Luo T, et al. Oxygen-self-produced nano-platform for relieving hypoxia and breaking resistance to sonodynamic treatment of pancreatic cancer. *Acta Nano.* (2017) 11:12849–6. doi: 10.21121/acsnano.7b008225

14. Stuehr DJ, Vasquez-Vivar J. Nitric oxide synthases: from genes to function. *Nitric Oxide.* (2017) 65:29. doi: 10.1016/j.niox.2017.01.005

15. Cao X, Ding L, Xie ZZ, Yang Y, Whiteman M, Moore PK, et al. A review of hydrogen sulfide synthesis, metabolism, and measurement: is modulation of hydrogen sulfide a novel therapeutic strategy for cancer? *Antioxid Redox Signal.* (2018) 31:1–38. doi: 10.1089/ars.2017.07058

16. Zhai X, Chen X, Ohta S, Sun X, Wu Q, et al. Protective effects of hydrogen-rich saline against erectile dysfunction in a streptozotocin induced diabetic rat model. *J Urol.* (2019) 193:350–6. doi: 10.1016/j.juro.2012.12.001

17. Zhang X, Liu J, Jin K, Xu H, Wang C, Zhang Z, et al. Subcutaneous injection of hydrogen gas is a novel effective treatment for type 2 diabetes. *Diabetes Investig.* (2018) 9:3–13. doi: 10.1111/dii.12674

18. Tamura T, Hayashida K, Sano M, Suzuki M, Shibusawa T, Yoshizawa J, et al. Feasibility and safety of hydrogen gas inhalation for post-cardiac arrest syndrome- first-in-human pilot study. *Circ J.* (2016) 80:1870–3. doi: 10.1253/circj.CJ-16-0127

19. Ge L, Yang M, Yang NN, Yin XX, Song WG. Molecular hydrogen: a preventive and therapeutic medical gas for various diseases. *Oncotarget.* (2017) 8:102653–73. doi: 10.18632/oncotarget.21130

20. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell Signal.* (2012) 24:981–90. doi: 10.1016/j.cellsig.2012.01.008

21. Kumar S, Badana AK, G MM, G S, Malla R. Reactive oxygen species: a key constituent in cancer survival. *Biomark Insights.* (2018) 13:91916689. doi: 10.1177/1772791918753391

22. Nita M, Grzybowski A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. *Oxid Med Cell Longev.* (2016) 2016:3164734. doi: 10.1155/2016/3164734

23. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. *Drug Resist Updat.* (2004) 7:97–110. doi: 10.1016/drup.2004.01.004

24. Liou GY, Stork P. Reactive oxygen species in cancer. *Free Radic. Res.* (2010) 44:479–96. doi: 10.1080/10715760903667554

25. Cui Q, Wang QJ, Assaraf YG, Ren L, Gupta P, Wei L, et al. Modulating ROS to overcome multidrug resistance in cancer. *Drug Resist. Update.* (2018) 41:1–25. doi: 10.1016/j.drup.2018.11.001

26. Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, et al. ROS signaling under metabolic stress: cross-talk between AMPK and Akt pathway. *Mol Cancer.* (2016) 17:69. doi: 10.1186/s12943-017-0648-1

27. Zha J, Chen F, Dong H, Shi P, Yao Y, Zhang Y, et al. Disulfiram increases the production of nitric oxide in brain tissue and redox regulation in cellular signaling. *Cell Signal.* (2017) 29:286–8. doi: 10.1016/j.cellsig.2017.02.006

28. Adriaenssens E, Philippe J, Desmyter J, Steegers-Theunissen RP. A potential role of NO in the modulation of tumor cell responses to chemotherapy. *Drug Resist. Updat.* (2019) 41:128–39. doi: 10.1016/j.drup.2018.11.001

29. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. *Drug Resist. Updat.* (2004) 7:97–110. doi: 10.1016/drup.2004.01.004

30. Liou GY, Stork P. Reactive oxygen species in cancer. *Free Radic. Res.* (2010) 44:479–96. doi: 10.1080/10715760903667554

31. Cui Q, Wang QJ, Assaraf YG, Ren L, Gupta P, Wei L, et al. Modulating ROS to overcome multidrug resistance in cancer. *Drug Resist. Update.* (2018) 41:1–25. doi: 10.1016/j.drup.2018.11.001

32. Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, et al. ROS signaling under metabolic stress: cross-talk between AMPK and Akt pathway. *Mol Cancer.* (2016) 17:69. doi: 10.1186/s12943-017-0648-1

33. Zha J, Chen F, Dong H, Shi P, Yao Y, Zhang Y, et al. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-κB pathway inhibition. *J Transl Med.* (2014) 12:165. doi: 10.1186/1479-5876-12-163

34. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. *Nat Rev Drug Discov.* (2013) 12:931–47. doi: 10.1038/nrd4002

35. Yu J, Yu Q, Liu Y, Zhang R, Xue L. Hydrogen gas alleviates oxygen toxicity by reducing hydroxyl radical levels in PC12 cells. *PLoS ONE.* (2017) 12:e0173645. doi: 10.1371/journal.pone.0173645
55. Shakola F, Suri P, Ruggiu M. Splicing regulation of pro-inflammatory cytokines and chemokines: at the interface of the neuroendocrine and immune systems. Biomolecules. (2015) 5:2073–100. doi: 10.3390/biom5032073

56. Bottazzi B, Riboli E, Mantovani A. Aging, inflammation, and cancer. Nat Rev Cancer. (2013) 13:842–57. doi: 10.1038/nrc3613

57. Zhou P, Lin B, Wang P, Pan T, Wang S, Chen W, et al. The healing effect of hydrogen-rich water protects against lipopolysaccharide-induced sepsis and attenuates liver injury. Shock. (2017) 48:85–93. doi: 10.1097/SHK.0000000000000810

58. Dong A, Yu Y, Wang Y, Li C, Chen H, Bian Y, et al. Protective effects of hydrogen gas against sepsis-induced acute lung injury via regulation of mitochondrial function and dynamics. Int Immunopharmacol. (2018) 65:366–72. doi: 10.1016/j.intimp.2018.10.012

59. Mager LF, Wasmer MH, Rau TT, Krebs P. Cytokine-induced modulation of colorectal cancer. Front Oncol. (2016) 6:96. doi: 10.3389/fonc.2016.00096

60. Ning K, Liu WW, Huang JL, Lu HT, Sun XJ. Effects of hydrogen on polarization of macrophages and microglia in a stroke model. Med Gas Res. (2018) 8:154–9. doi: 10.4103/mgr.mgr_28_18

61. Zhang N, Deng C, Zhang X, Zhang J, Bai C. Inhalation of hydrogen gas alleviates airway inflammation and oxidative stress in allergic asthmatic mice. Asthma Res Pract. (2018) 4:3–8. doi: 10.1186/s40733-018-0040-y

62. Wardill HR, Mander KA, Van Sebille YZ, Gibson RJ, Logan RM, Bowen JM, et al. Cytokine-mediated blood brain barrier disruption as a conduit for cancer chemotherapy-associated neurotoxicity and cognitive dysfunction. Int J Cancer. (2016) 139:2635–45. doi: 10.1002/ijc.30252

63. Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol. (2015) 26:1446–51. doi: 10.1093/annonc/mdv206

64. Vyas D, Laput G, Vyas AK. Cytokine-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther. (2014) 7:1015–23. doi: 10.2147/OTT.S60114

65. Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci. (2019) 20:6767. doi: 10.3390/ijms2003676

66. Li FY, Zhu SX, Wang ZP, Wang H, Zhao Y, Chen GP. Consumption of hydrogen-rich water protects against ferric nitrolactate-induced nephrotoxicity and early tumor promotion events in rats. Food Chem Toxicol. (2013) 61:248–54. doi: 10.1016/j.fct.2013.10.004

67. Huang D, Ichikawa K. Drug discovery targeting apoptosis. Nat Rev Drug Discov. (2008) 7:1041. doi: 10.1038/nrd2765

68. Pfeffer CM, Singh A. Apoptosis: a target for anticancer therapy. Int J Mol Sci. (2018) 19:4448. doi: 10.3390/ijms19020448

69. Qiao L, Wong BC. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist Updat. (2009) 12:55–64. doi: 10.1016/j.drup.2009.02.002

70. Kumar S. Caspase 2 in mouse tumors, the DNA damage response and tumour suppression: enigma no more? Nat Rev Cancer. (2009) 9:897–903. doi: 10.1038/nrc2745

71. Gao Y, Yang H, Fan Y, Li L, Fang J, Yang W. Hydrogen-rich saline attenuates cardiac and hepatic injury in doxorubicin rat model by inhibiting inflammation and apoptosis. Mediators Inflamm. (2016) 2016:320365. doi: 10.1155/2016/320365

72. Li Q, Tanaka Y, Miwa N. Influence of hydrogen-occluding-silica on migration and apoptosis in human esophageal cells in vitro. Med Gas Res. (2017) 7:76–85. doi: 10.4103/2045-9912.208510

73. Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, et al. The chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun. (2019) 39:10. doi: 10.1186/s40880-019-0349-9

74. Verheij M, Vens C, van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat. (2010) 13:29–43. doi: 10.1016/j.drup.2010.01.002

75. Sun YJ, Hu YJ, Jin D, Li JW, Yu R. Health-related quality of life after treatment for malignant bone tumors: a follow-up study in China. Asian Pac J Cancer Prev. (2012) 13:3099–100. doi: 10.7314/APJCP.2012.13.7.3099

76. Susanne K, Michael F, Thomas S, Peter E, Andreas H. Predictors of fatigue in cancer patients: a longitudinal study. Support Care Cancer. (2019) 120:425–32. doi: 10.1007/s00520-019-4660-4

77. Razzaghoudt A, Mofid B, Peyghambarlou P. Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy. Support Care Cancer. (2019). doi: 10.1007/s00520-019-04780-7. [Epub ahead of print].

78. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. (2006) 10:175–7. doi: 10.1016/j.cccr.2006.08.015

79. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. (2003) 361:1317–9. doi: 10.1016/S0140-6736(03)12190-3

80. Terasaki Y, Suzuki T, Tonaki K, Terasaki M, Kawaihara N, Ohsiro J, et al. Molecular hydrogen attenuates gefitinib-induced exacerbation of naphthalene-evoked acute lung injury through a reduction in oxidative stress and inflammation. Invest Lung Dis. (2019) 99:793–806. doi: 10.1111/ilj.13121

81. Terasaki Y, Suzuki T, Tonaki K, Terasaki M, Kuwahara N, Ohsiro J, et al. Molecular hydrogen attenuates gefitinib-induced exacerbation of naphthalene-evoked acute lung injury through a reduction in oxidative stress and inflammation. Invest Lung Dis. (2019) 99:793–806. doi: 10.1111/ilj.13121

82. Kumar S. Caspase 2 in apoptosis, the DNA damage response and cell death. Front Oncol. (2017) 7:1015–23. doi: 10.3389/fonc.2017.00154

83. Matsushita T, Kusakabe Y, Kitamura A, Okada S, Murase K. Experimental verification of protective effect of hydrogen-rich water against cisplatin-induced nephrotoxicity in rats using dynamic contrast-enhanced level-dependent magnetic resonance imaging. Jpn J Radiol. (2015) 33:809–16. doi: 10.1186/s11604-015-0588-4

84. Kitamura A, Kobayashi S, Matsuhashi T, Fujinawa H, Murase K. Experimental verification of protective effect of hydrogen-rich water against cisplatin-induced nephrotoxicity in rats using dynamic contrast-enhanced CT. Br J Radiol. (2010) 83:598–600. doi: 10.1259/bjr/25604811

85. Nakashima-Kamimura N, Mori T, Ohwasa I, Asoh S, Ohta S. Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice. Cancer Chemother Pharmacol. (2009) 64:735–41. doi: 10.1007/s00280-008-0924-2

86. Meng X, Chen H, Wang G, Yu X, Xie K. Hydrogen-rich saline attenuates chemotherapy-induced ovarian injury via regulation of oxidative stress. Exp Ther Med. (2015) 10:2277–82. doi: 10.3892/etm.2015.2578

87. Marco MR, Zhou L, Patil S, Marcket JE, Varma MG, Oommen S, et al. Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final
results of a multicenter phase II trial. *Dis Colon Rectum*. (2018) 61:1146–55. doi: 10.1097/DCR.0000000000001207

88. Horimatsu T, Nakayama N, Moriwaki T, Hirashima Y, Fujita M, Asayama M, et al. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin. (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. *Int J Clin Oncol*. (2017) 22:905–12. doi: 10.1007/s10147-017-1138-6

89. Chuai Y, Zhao L, Ni J, Sun D, Cui J, Li B, et al. A possible prevention strategy of radiation pneumonitis combine radiotherapy with aerosol inhalation of hydrogen-rich solution. *Med Sci Monit*. (2011) 17:Y1-4. doi: 10.12659/MSM.881698

90. Mei K, Zhao S, Qian L, Li B, Ni J, Cai J. Hydrogen protects rats from dermatitis caused by local radiation. *J Dermatolog Treat*. (2014) 25:182–8. doi: 10.3109/09546634.2012.762639

91. Rodriguez ML, Martin MM, Padellano LC, Palomo AM, Puebla YI. Gastrointestinal toxicity associated to radiation therapy. *Clin Transl Oncol*. (2010) 12:554–61. doi: 10.1007/s12094-010-0553-1

92. Xiao HW, Li Y, Luo D, Dong JL, Zhou LX, Zhao SY, et al. Hydrogen-water ameliorates radiation-induced gastrointestinal toxicity via MyD88’s effects on the gut microbiota. *Exp Mol Med*. (2018) 50:e433. doi: 10.1038/emm.2017.246

93. Kang KM, Kang YN, Choi IB, Gu Y, Kawamura T, Toyoda Y, et al. Effects of drinking hydrogen-rich water on the quality of life of patients treated with radiotherapy for liver tumors. *Med Gas Res*. (2011) 1:11. doi: 10.1186/2045-9912-1-11

94. Phan J, Ng V, Sheinbaum A, French S, Choi G, El KM, et al. Hyperlipidemia and nonalcoholic steatohepatitis predispose to hepatocellular carcinoma development without cirrhosis. *J Clin Gastroenterol*. (2019) 53:309–13. doi: 10.1097/MCG.0000000000001062

95. Ma C, Zhang Q, Greten TF. Non-alcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes. *Fibs J*. (2018) 285:752–62. doi: 10.1111/fibs.14209

96. Kawai D, Takaki A, Nakatsuka A, Wada J, Tamaki N, Yasunaka T, et al. Hydrogen-rich water prevents progression of non-alcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. *Hepatology*. (2012) 56:912–21. doi: 10.1002/hep.25782

97. Kisselah AH, Sonnenberg GE, Myklebust J, Goldstein M, Bromlan K, James RG, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. *Proc Natl Acad Sci USA*. (2000) 97:14478–83. doi: 10.1073/pnas.97.26.14478

98. Wang D, Wang L, Zhang Y, Zhao Y, Chen G. Hydrogen gas inhibits lung cancer progression through targeting SMC3. *Biomed Pharmacother*. (2018) 104:788–97. doi: 10.1016/j.biopharm.2018.05.055

99. Shang L, Xie F, Li J, Zhang Y, Liu M, Zhao P, et al. Therapeutic potential of molecular hydrogen in ovarian cancer. *Transl Cancer Res*. (2018) 7:988–9. doi: 10.21037/tcr.2017.12.09

100. Liu MY, Xie F, Zhang Y, Wang TT, Ma SN, Zhao PX, et al. Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation. * Stem Cell Res Ther*. (2019) 10:145. doi: 10.1186/s13287-019-1241-x

101. Zhang JY, Liu C, Zhou L, Qu K, Wang R, Tai MH, et al. A review of hydrogen as a new medical therapy. *Hepatogastroenterology*. (2012) 59:1026–32. doi: 10.5755/hge11883

102. Ohta S. Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications. *Curr Pharm Des*. (2011) 17:2241–52. doi: 10.2174/138161211797052664

103. Dixon BJ, Tang J, Zhang JH. The evolution of molecular hydrogen: a noteworthy potential therapy with clinical significance. *Med Gas Res*. (2013) 3:10. doi: 10.1186/2045-9912-3-10

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.